United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Back to dashboard
Company Information
About this company
Key people
Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Michael Benkowitz
President and Chief Operating Officer
Christopher Patusky
Lead Independent Vice Chairman of the Board
James C. Edgemond
Chief Financial Officer and Treasurer
Paul A. Mahon
Executive Vice President, General Counsel, and Corporate Secretary
Victor Dzau
Director
Christopher A. Causey
Independent Director
Richard A. Giltner
Independent Director
Raymond C. Kurzweil
Independent Director
Click to see more
Key facts
- Shares in issue78.24m
- EPICUTHR
- ISINUS91307C1027
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$22.87bn
- Employees1,400
- ExchangeNASDAQ
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.